

Valentin Brodszky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5312855/publications.pdf>

Version: 2024-02-01

105
papers

3,176
citations

218381

26
h-index

189595

50
g-index

125
all docs

125
docs citations

125
times ranked

3750
citing authors

#	ARTICLE	IF	CITATIONS
1	The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. <i>Human Reproduction</i> , 2012, 27, 1292-1299.	0.4	732
2	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.4	144
3	Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 65-71.	1.4	108
4	EQ-5D in Central and Eastern Europe: 2000â€“2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	1.5	103
5	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
6	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
7	Adherence to biologic DMARD therapies in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1367-1378.	1.4	60
8	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	1.4	60
9	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
10	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	1.5	51
11	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 31-42.	1.4	50
12	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	0.9	47
13	Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 303-309.	0.6	45
14	A budget impact model for biosimilar infliximab in Crohnâ€™s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44
15	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.4	42
16	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	1.3	41
17	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
18	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohnâ€™s disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	1.5	41

#	ARTICLE	IF	CITATIONS
19	A detailed analysis of "not relevant"™ responses on the <sc>DLQI</sc> in psoriasis: potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 783-790.	1.3	40
20	Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatology International, 2009, 30, 199-205.	1.5	36
21	Access to biologicals in Crohn's™ disease in ten European countries. World Journal of Gastroenterology, 2017, 23, 6294.	1.4	35
22	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry, 2019, 26, 259-269.	1.2	34
23	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. PLoS ONE, 2014, 9, e107704.	1.1	31
24	Costs of dementia in Hungary. Journal of Nutrition, Health and Aging, 2010, 14, 633-639.	1.5	30
25	Treatment preferences of originator versus biosimilar drugs in Crohn's™ disease; discrete choice experiment among gastroenterologists. Scandinavian Journal of Gastroenterology, 2016, 51, 22-27.	0.6	30
26	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. Pain, 2017, 158, 2259-2267.	2.0	30
27	Validity of the <sc>EQ</sc> â€5D in patients with pemphigus vulgaris and pemphigus foliaceus. British Journal of Dermatology, 2019, 180, 802-809.	1.4	27
28	Costs of rheumatoid arthritis in Hungary. Journal of Rheumatology, 2007, 34, 1437.	1.0	27
29	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. European Journal of Health Economics, 2014, 15, 53-64.	1.4	26
30	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. European Journal of Health Economics, 2019, 20, 43-55.	1.4	25
31	DLQIâ€™R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. British Journal of Dermatology, 2020, 182, 1167-1175.	1.4	25
32	Validity of EQâ€5Dâ€L, Skindexâ€16, DLQI and DLQIâ€™R in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2584-2592.	1.3	25
33	Subjective expectations regarding length and healthâ€™related quality of life in <sc>H</sc>ungary: results from an empirical investigation. Health Expectations, 2014, 17, 696-709.	1.1	24
34	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. British Journal of Dermatology, 2015, 173, 1076-1080.	1.4	24
35	Is the DLQI appropriate for medical decision-making in psoriasis patients?. Archives of Dermatological Research, 2018, 310, 47-55.	1.1	24
36	Cost-of-illness studies in nine Central and Eastern European countries. European Journal of Health Economics, 2019, 20, 155-172.	1.4	23

#	ARTICLE	IF	CITATIONS
37	Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. <i>European Journal of Health Economics</i> , 2014, 15, 101-109.	1.4	22
38	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
39	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	1.3	21
40	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.5	21
41	Association between quality of life and clinical characteristics in patients with morphea. <i>Quality of Life Research</i> , 2018, 27, 2525-2532.	1.5	21
42	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. <i>European Journal of Health Economics</i> , 2014, 15, 83-92.	1.4	20
43	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20
44	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
45	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	1.3	19
46	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.3	19
47	Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. <i>Archives of Iranian Medicine</i> , 2015, 18, 153-9.	0.2	19
48	Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?. <i>European Journal of Health Economics</i> , 2019, 20, 133-140.	1.4	18
49	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
50	Subjective health expectations of patients with age-related macular degeneration treated with anti-VEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	1.1	17
51	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	1.4	17
52	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	2.1	17
53	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	1.5	16
54	Expression of G protein-coupled oestrogen receptor in melanoma and in pregnancy-associated melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1453-1461.	1.3	16

#	ARTICLE	IF	CITATIONS
55	A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-6* and Skindex-16*. British Journal of Dermatology, 2022, 186, 485-495.	1.4	16
56	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. British Journal of Dermatology, 2016, 175, 593-599.	1.4	15
57	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 139-147.	0.7	15
58	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 27-34.	1.4	14
59	Exploring the identification, validation, and categorization of costs and benefits of education in mental health: The PECUNIA project. International Journal of Technology Assessment in Health Care, 2020, 36, 325-331.	0.2	13
60	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. Quality of Life Research, 2020, 29, 2863-2874.	1.5	13
61	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 399-408.	0.7	13
62	In Search for Comparability: The PECUNIA Reference Unit Costs for Health and Social Care Services in Europe. International Journal of Environmental Research and Public Health, 2022, 19, 3500.	1.2	13
63	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. European Journal of Health Economics, 2014, 15, 73-82.	1.4	12
64	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. European Journal of Health Economics, 2019, 20, 141-154.	1.4	12
65	The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Quality of Life Research, 2021, 30, 1477-1490.	1.5	12
66	Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review. Value in Health, 2021, 24, 1158-1171.	0.1	12
67	Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scandinavian Journal of Rheumatology, 2008, 37, 399-400.	0.6	11
68	Cost of illness of medically treated benign prostatic hyperplasia in Hungary. International Urology and Nephrology, 2015, 47, 1241-1249.	0.6	11
69	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues, 2016, 10, 85-90.	0.5	11
70	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. European Journal of Health Economics, 2019, 20, 17-30.	1.4	11
71	Exploring the identification, validation, and categorization of the cost and benefits of criminal justice in mental health: the PECUNIA project. International Journal of Technology Assessment in Health Care, 2020, 36, 418-425.	0.2	11
72	A Rasch model analysis of two interpretations of "not relevant" responses on the Dermatology Life Quality Index (DLQI). Quality of Life Research, 2021, 30, 2375-2386.	1.5	10

#	ARTICLE	IF	CITATIONS
73	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	1.5	9
74	Disease burden of patients with pemphigus from a societal perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 77-86.	0.7	9
75	Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients. <i>Life</i> , 2021, 11, 919.	1.1	9
76	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	1.4	8
77	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. <i>Value in Health Regional Issues</i> , 2020, 22, 61-67.	0.5	8
78	Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2106-2113.	1.3	7
79	Subjective well-being in patients with pemphigus: a path analysis. <i>European Journal of Health Economics</i> , 2019, 20, 101-107.	1.4	7
80	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
81	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	1.3	7
82	Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. <i>Medical Science Monitor</i> , 2010, 16, SR1-5.	0.5	7
83	Health status and costs of ambulatory patients with multiple sclerosis in Hungary. <i>Ideggyogyaszati Szemle</i> , 2012, 65, 316-24.	0.4	7
84	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	1.4	6
85	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
86	Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters. <i>Life</i> , 2021, 11, 535.	1.1	6
87	(Pharmaco)economic evaluations for mental health related services: the PECUNIA project. <i>European Journal of Public Health</i> , 2020, 30, .	0.1	6
88	Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. <i>European Journal of Health Economics</i> , 2023, 24, 139-152.	1.4	6
89	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	0.6	5
90	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Antidrug antibody formation during tumor necrosis factor $\hat{\pm}$ inhibitor treatment of severe psoriatic patients in the real-life practice. <i>Postepy Dermatologii I Alergologii</i> , 2019, 36, 589-594.	0.4	5
92	General and Skin-Specific Health-Related Quality of Life in Patients With Atopic Dermatitis Before and During the COVID-19 Pandemic. <i>Dermatitis</i> , 2022, 33, S92-S103.	0.8	5
93	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	1.4	4
94	Measurement properties of the ICECAP-A capability well-being instrument among dermatological patients. <i>Quality of Life Research</i> , 2022, 31, 903-915.	1.5	4
95	Comparing self-perceived and estimated fracture risk by FRAX [®] of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	1.0	3
96	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3
97	Productivity Loss in Patients With Chronic Diseases: A Pooled Economic Analysis of Hungarian Cost-of-Illness Studies. <i>Value in Health Regional Issues</i> , 2020, 22, 75-82.	0.5	3
98	The relationship between IL-6 and thrombocytosis accompanying gastrointestinal tumours. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 215-219.	0.3	2
99	Subjective expectations regarding longevity and future health: a cross-sectional survey among patients with Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 105-113.	0.7	2
100	Narrow Vagina as a Predictor of Obstructive Voiding Dysfunction after Transobturator Sling Surgery. <i>Urologia Internationalis</i> , 2021, 105, 1092-1098.	0.6	2
101	QUALITY OF LIFE OF PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN; RESULTS FROM A CROSS-SECTIONAL SURVEY IN GENERAL PRACTICES IN HUNGARY. <i>Ideggyogyaszati Szemle</i> , 2015, 68, 325-30.	0.4	2
102	Social Utility Values for Pemphigus Vulgaris and Foliaceus: A Composite Time Trade-Off Study. <i>Value in Health</i> , 2015, 18, A673.	0.1	1
103	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	0.6	1
104	Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 291-303.	1.0	1
105	Assessment of health state utilities in dermatology: an experimental time trade-off value set for the dermatology life quality index. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	1.0	1